Researchers of the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial reported at the 2023 IGCS Meeting that selinexor extended progression-free survival (PFS) in TP53 wild-type advanced or recurrent endometrial cancer. Involving 263 patients, selinexor significantly outperformed placebo, showing a median PFS of 27.4 vs 5.2 months. These results indicate TP53 wild-type status as a potential marker for selinexor response, leading to a new trial focusing on its maintenance therapy.
Reference: Wahner A. Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer. OncLive. Published November 22, 2023. Accessed December 20, 2023. https://www.onclive.com/view/selinexor-maintenance-leads-to-pfs-benefit-in-tp53-wild-type-advanced-recurrent-endometrial-cancer
